PIK3CD and cancer: A recent study also showed that inhibition of the p110δ PI3K isoform in regulatory T cells triggers antitumor immune response, indicating an alternative pathway through which PI3K inhibitors could target cancers which are not directly driven by PI3K overactivation [12].